The utilisation of endocrine and immunotherapy: Retrospective study at a tertiary hospital in South Africa

Read full text Summarise with VIRAT
Authors: Kgabo Ambros Mashishi, Tebogo L. Manyama, Bonelwa Sidumo
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Cancer remains a major public health concern globally and within sub-Saharan Africa, accounting for a substantial proportion of morbidity and mortality. Immunotherapy boosts the immune system against cancer, while endocrine therapy is typically used in cancer patients diagnosed with hormone receptor-positive cancers. Breast and prostate cancers are the most prevalent cancers in which endocrine therapy and immunotherapy are utilised. This study aimed to evaluate the use of endocrine and immunotherapy, and factors associated with their use at a tertiary hospital in Limpopo Province, South Africa. Method A retrospective open cohort, longitudinal, descriptive study design was utilised. The study enrolled 82 (eighty-two) medical records of patients who started cancer treatment from January 2019 to August 2025 at a tertiary hospital in Limpopo Province of South Africa. A Chi-square or ANOVA test was used to examine the association between age, receptor status, and cancer stage at diagnosis with the type of first-line therapy. Data analysis was conducted using R programming software, version 4.5.2. Results Endocrine therapy was used as primary or first- line treatment in 29.3% ( \(n=\)24) of the patients and was dominantly used as an adjuvant therapy to chemotherapy. The analysis indicated a significant association between age, cancer stage, receptor status, and the use of endocrine therapy as first-line treatment. None of the patients received immunotherapy as first-line treatment at diagnosis. The results further revealed limited use of immunotherapy to a maximum of 5 patients over the study period. Conclusion While endocrine therapy is predominantly used as an adjuvant therapy to chemotherapy, the use of immunotherapy is limited. This reveals that patients who would normally benefit from immunotherapy may not be receiving it. This may be due to the cost implications and budget constraints in the public hospitals.

Fields of Study & Subjects

Breast Cancer Treatment Studies Advanced Breast Cancer Therapies Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
Research Square
Publication date
28 March 2026
Language
EN
Document type
Preprint